We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MOBX:NASDAQMobix Labs, Inc. Analysis

Data as of 2026-07-08 - not real-time

$2.09

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Mobix Labs (MOBX) is trading at $2.09, just above the calculated support of $1.84 and marginally above its 20‑day SMA of $2.08, while sitting well below both the 50‑day SMA ($2.21) and the 200‑day SMA ($4.25), indicating a bearish longer‑term trend. The RSI of 48 is neutral, and the MACD histogram has turned positive (0.028) despite the MACD line remaining negative, giving a brief bullish signal that is being offset by a bearish overall trend direction and decreasing volume. Volatility is extreme at 73% over the past 30 days and the beta of –2.23 suggests the stock moves inversely and more aggressively than the market, contributing to a high overall risk profile. The market sentiment index reads “Extreme Greed” (88.2), yet the stock’s price‑to‑book (2.49) and price‑to‑sales (4.49) multiples appear stretched given the company’s fundamentals.
Fundamentally, MOBX reports a 61% revenue decline, negative gross margin (43%), operating losses of –6.28%, zero earnings per share, and a massive max drawdown of –87.9%, underscoring severe profitability challenges. The balance sheet shows $6.66 M of debt versus $2.56 M of cash, yielding a debt‑to‑equity of 75% and negative free cash flow, which amplifies liquidity concerns. Recent material news includes a binding Letter of Intent to acquire Vision Aerial, a U.S. drone manufacturer, and inclusion in the Russell Microcap Index, both of which could provide a growth catalyst but also add integration risk in the near term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent acquisition announcement driving short‑term price momentum
  • Technical support near $1.84 and slight MACD bullish crossover
  • High volatility and decreasing volume increasing trade risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Integration risk of Vision Aerial acquisition
  • Continued negative earnings and cash flow
  • Potential upside from Russell Microcap inclusion and sector exposure

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Sustained operating losses and high debt burden
  • Extreme price volatility and historical drawdown
  • Unclear path to profitability despite growth initiatives

Key Metrics & Analysis

Financial Health

Revenue Growth-61.40%
ROE-870.34%
ROA-51.54%
Debt/Equity75.28
P/B Ratio2.5
Op. Cash Flow$-17614000
Free Cash Flow$-7274875
Industry P/E33.0

Technical Analysis

TrendBearish
RSI48.0
Support$1.84
Resistance$2.46
MA 20$2.08
MA 50$2.21
MA 200$4.25
MACDBullish
VolumeDecreasing
Fear & Greed Index88.18

Valuation

GradeOvervalued
TypeBlend

Risk Assessment

Beta-2.23
Volatility73.06%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.